Expand MLYS Menu
MLYS MENU

MLYS Latest Press Releases

-- August 26, 2026 --

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference Globe Newswire 8:00 AM

-- August 13, 2026 --

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 11, 2026 --

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- August 4, 2026 --

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 Globe Newswire 8:00 AM

-- July 27, 2026 --

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- June 14, 2026 --

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Globe Newswire 10:00 AM

-- June 8, 2026 --

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Globe Newswire 4:05 PM
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) Globe Newswire 7:00 AM

-- June 3, 2026 --

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock Globe Newswire 6:05 AM
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing Globe Newswire 6:00 AM

-- May 30, 2026 --

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) Globe Newswire 11:15 AM

-- May 27, 2026 --

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference Globe Newswire 8:00 AM

-- May 18, 2026 --

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) Globe Newswire 4:05 PM

-- May 6, 2026 --

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- May 5, 2026 --

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:34 PM
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference Globe Newswire 8:00 AM

-- April 29, 2026 --

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes